Libtayo Earns European Approval for Advanced Squamous Cell Cancer

The European Commission cleared Regeneron and Sanofi’s Libtayo (cemiplimab) for treating adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC).

The green light makes the treatment available to patients that aren’t eligible for surgery or radiation to treat the skin cancer.

With the marketing authorization, the fully-human monoclonal antibody becomes the only approved treatment for advanced CSCC in the European Union.